Skip to main content
Addgene

CEBPalpha NGFR
(Plasmid #44627)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 44627 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    NGFR (Addgene plasmid 27489)
  • Backbone manufacturer
    Warren Pear lab
  • Backbone size w/o insert (bp) 6500
  • Vector type
    Mammalian Expression, Retroviral

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    CEBPalpha
  • Alt name
    Cebpa
  • Alt name
    Cebpa CCAAT/enhancer binding protein (C/EBP), alpha binding protein
  • Species
    M. musculus (mouse)
  • Insert Size (bp)
    1098
  • Entrez Gene
    Cebpa (a.k.a. C/ebpalpha, CBF-A, Cebp)
  • Tags / Fusion Proteins
    • IRES (C terminal on backbone)
    • truncated NGFR (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site BglII (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer pBABE-5
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    CEBPalpha NGFR was a gift from Ellen Rothenberg (Addgene plasmid # 44627 ; http://n2t.net/addgene:44627 ; RRID:Addgene_44627)
  • For your References section:

    Architecture of a lymphomyeloid developmental switch controlled by PU.1, Notch and Gata3. Del Real MM, Rothenberg EV. Development. 2013 Mar;140(6):1207-19. doi: 10.1242/dev.088559. 10.1242/dev.088559 PubMed 23444353